Health Care - Spark Newswire

1 minute read

Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise

Today, 7:35 PM

Cyclerion Therapeutics Inc (NASDAQ:CYCN) has entered into an exclusive, global license agreement with Akebia Therapeutics Inc (NASDAQ:AKBA) for the development and commercialization of…

AKBA

1 minute read

FDA Expands EUA for Lower Dose Subcutaneous Version of Regeneron’s COVID-19 Antibody Cocktail

By Vandana Singh

Today, 7:35 PM

The FDA has authorized a new, lower-dose version of Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) COVID-19 monoclonal antibody cocktail for those with COVID-19 who…

REGN

1 minute read

Surface Oncology’s SRF388 Shows Promising Anticancer Activity in Pretreated Patients

By Vandana Singh

Today, 7:35 PM

Surface Oncology (NASDAQ:SURF) has announced new data from the ongoing Phase 1 studies of SRF388 and SRF617. SRF388 data will be…

SURF

1 minute read

4D pharma To Stop Testing Asthma Med in COVID-19 Patients

By Vandana Singh

Today, 7:35 PM

4D pharma plc (NASDAQ: LBPS) has completed its target enrollment of 30 patients for Part A of its Phase 1/2 trial of MRx-4DP0004 in patients with partly controlled asthma.

LBPS

1 minute read

Sanofi Inks Partnership for Late-Stage Trial of Amcenestrant as Add-On Breast Cancer Therapy

By Vandana Singh

Today, 7:35 PM

Sanofi SA (NASDAQ:SNY) has secured partners for a Phase 3 trial to study amcenestrant versus the hormone therapy tamoxifen in breast…

SNY

1 minute read

Surface Oncology, Roche Team Up to Develop SRF388 Combo Therapy for Liver Cancer

By Vandana Singh

Today, 7:35 PM

Surface Oncology (NASDAQ:SURF) has entered into a clinical trial collaboration with Roche Holdings AG (OTC:RHHBY) to evaluate former’s SRF388, anti-IL-27 antibody, in combination…

RHHBF

1 minute read

Coherus, Junshi Toripalimab-Chemo Combo Beat Chemo Alone in Late-Stage Nose & Throat Cancer Trial

By Vandana Singh

Today, 7:35 PM

Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ:CHRS) have announced positive results from the pivotal Phase 3 JUPITER-02 trial evaluating toripalimab…

CHRS